AIRNA, a cutting-edge biotech firm specializing in RNA editing therapeutics, has successfully closed an oversubscribed $60 million Series A financing round, pushing the total raised to $90 million. This investment, led by Forbion and supported by a prestigious group of investors including ARCH Venture Partners, Ono Venture Investment, Alexandria Venture Investments, and ND Capital, will advance AIRNA’s pioneering product candidates into clinical trials.
Kris Elverum, President and CEO of AIRNA, emphasized the strategic significance of this funding: “This Series A financing unites a unique syndicate of investors committed to realizing AIRNA’s vision of revolutionizing therapeutic approaches through base editing. Our goal is to initiate clinical trials for our lead drug candidate within the next year and to further develop our RESTORE+™ platform to target previously inaccessible genetic conditions.”
Founded with backing from ARCH Venture Partners, AIRNA is at the forefront of RNA editing, leveraging groundbreaking research from academic co-founders Thorsten Stafforst of the University of Tübingen and Jin Billy Li of Stanford University. The company’s RESTORE+™ platform is designed to enhance oligonucleotide sequences, chemistry, and delivery mechanisms, positioning AIRNA as a leader in precision RNA therapeutics. Their flagship product aims to provide a potential best-in-class treatment for alpha-1 antitrypsin deficiency (AATD), a genetic disorder causing severe lung and liver disease.
In a strategic move, AIRNA also announced the appointment of Josh Brumm, General Partner at Forbion, to its Board of Directors. Brumm, who previously served as CEO of Dyne Therapeutics, brings extensive expertise in oligonucleotide-based therapies. Brumm commented, “AIRNA’s innovative approach to RNA editing holds the promise of transformative outcomes for patients with AATD and other severe diseases. We are thrilled to support their exceptional team and contribute to their journey toward becoming a leading force in genetic medicine.”
Editorial Opinion:
AIRNA’s recent funding success marks a pivotal moment for the biotech landscape, underscoring the growing confidence in RNA editing as a transformative approach to treating genetic diseases. The substantial investment led by Forbion, alongside a consortium of high-profile venture capitalists, reflects strong belief in AIRNA’s potential to redefine therapeutic boundaries.
The company’s RESTORE+™ platform stands out for its innovative technology that aims to tackle diseases previously deemed intractable by traditional methods. With a distinguished team, including pioneering researchers and seasoned industry professionals like Josh Brumm, AIRNA is well-positioned to make significant strides in the RNA therapeutics field. Their focused strategy on advancing a best-in-class treatment for AATD, coupled with a broad pipeline of potential therapies, suggests a promising trajectory that could lead to substantial advancements in genetic medicine.
If you need further assistance or have any corrections, please reach out to editor@thetimesmag.com.
